AbbVie: Number of Employees 2010-2023 | ABBV

Interactive chart of AbbVie (ABBV) annual worldwide employee count from 2010 to 2023.
  • AbbVie total number of employees in 2023 was 50,000, a 0% decline from 2022.
  • AbbVie total number of employees in 2022 was 50,000, a 0% decline from 2021.
  • AbbVie total number of employees in 2021 was 50,000, a 6.38% increase from 2020.
  • AbbVie total number of employees in 2020 was 47,000, a 56.67% increase from 2019.
AbbVie Annual Employee Count
2023 50,000
2022 50,000
2021 50,000
2020 47,000
2019 30,000
2018 30,000
2017 29,000
2016 30,000
2015 28,000
2014 26,000
2013 25,000
2012 21,500
2011 21,000
2010
2009
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $294.653B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67